A Study of HS135 for the Treatment of Pulmonary Arterial Hypertension in Adults
Phase 1b, Multicenter, Open-Label, Multiple Ascending Dose Study Assessing the Pharmacokinetics, Safety, Pharmacodynamics, and Efficacy of HS135 Added to Background Pulmonary Arterial Hypertension (PAH) Therapy
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Detailed Description
Study Type
Study Type
Enrollment (Actual)
Enrollment
Phase
Phase
- Phase 1
Contacts and Locations
Study Contact
Study Contact
- Name: Danaë Lemieux-Uresandi, M.Sc
- Phone Number: +1 (514) 448 1814
- Email: clinicaltrials@35pharma.com
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
- Adult
- Older Adult
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- Male and female patients, 18 years of age and older.
- Body Mass Index (BMI) 18.5 and 40 kg/m2 and body weight at or below 120 kg
- Documented diagnostic RHC at any time prior to screening.
- Diagnosis of WHO PAH Group 1.
- Symptomatic PAH classified as WHO FC II to IV.
- Baseline RHC performed during the Screening Period documenting a minimum PVR of ≥ 5 Wood units (WU) or ≥ 400 dyn・sec・cm-5 and a pulmonary artery wedge pressure (PAWP) of ≤ 15 mmHg.
- On stable doses of at least 2 background PAH therapies.
Exclusion Criteria:
- Left ventricular ejection fraction < 50% at screening.
- Any symptomatic coronary disease events within 6 months of the screening visit.
- Uncontrolled systemic hypertension.
- History of restrictive, constrictive or congestive cardiomyopathy.
- History of atrial septostomy.
- Patients who have an abnormality in the Echocardiogram or in the 12-lead ECG that, in the opinion of the Investigator, increases the risk of participating in the study.
- Pulmonary function test (PFT) values of forced vital capacity (FVC) and or FEV1 < 60% predicted at the screening visit or within 6 months prior to the screening visit.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: N/A
- Interventional Model: Sequential Assignment
- Masking: None (Open Label)
Number of Arms
Arms and Interventions
Participant Group / ArmParticipant Group / Arm |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
Experimental: HS135
Subcutaneous Injection
|
HS135 is dosed subcutaneously
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Adverse Events (AEs)
Time Frame: Up to 24 weeks
|
Up to 24 weeks
|
|
|
Change from Baseline in Physical Examination
Time Frame: Up to 24 weeks
|
Physical Examination will include the assessment of body systems.
|
Up to 24 weeks
|
|
Change from Baseline in Clinical Laboratory Parameters
Time Frame: Up to 24 weeks
|
Up to 24 weeks
|
|
|
Change from Baseline in Blood Pressure
Time Frame: Up to 24 weeks
|
Up to 24 weeks
|
Collaborators and Investigators
Sponsor
Sponsor
Investigators
Investigators
- Study Director: Monique Champagne, M.Sc., VP, Clinical Operations
Study record dates
Study Major Dates
Study Start (Actual)
Study Start
Primary Completion (Actual)
Primary Completion
Study Completion (Actual)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Actual)
First Posted
Study Record Updates
Last Update Posted (Actual)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
Other Study ID Numbers
- HS135-002
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.